Purpose
The main goal of the NIH Tetramer Facility is to provide MHC class I and class II tetramer reagents to the research community. Tetramers available through the Facility include: (1) custom-made human, macaque, chimp, and mouse class I tetramers; (2) human and mouse CD1d tetramers with or without PBS-57 (PBS-57 ligand provided by Dr. Paul Savage, Brigham Young University); and (3) pre-made and custom-made human and mouse MHC class II tetramers.

This program is funded by the National Institute of Allergy and Infectious Diseases and the National Cancer Institute, components of the National Institutes of Health, Department of Health and Human Services.

Operation
Dr. John Altman is the Principal Investigator of the NIH Tetramer Facility, Dr. Rick Willis is the Technical Director, and Dale Long is the Facility Manager. Overall program supervision is conducted by Dr. Alison Deckhut Augustine at the NIAID with input from the Tetramer Resource Committee (TRC), and all general questions regarding Tetramer Facility operations and the request process should be directed to Dr. Deckhut Augustine.

Reagent requests are submitted on-line using request forms available at the NIH Tetramer Facility website. The TRC reviews and prioritizes all tetramer reagent requests. After submission and prior to approval, the processing of tetramer requests is managed by the Facility Manager, Dale Long. Questions regarding previously submitted requests that have not yet been approved as well as questions concerning registration with the Facility should be directed to Mr. Long or Dr. Deckhut Augustine.

After approval, questions regarding tetramer requests should be directed to Dale Long. Questions about technical issues related to tetramer usage should be sent to Dr. Rick Willis.

Location
The NIH Tetramer Facility is part of the Emory Vaccine Center located in the Yerkes National Primate Research Center at Emory University in Atlanta, GA.